REFERENCES

1. Hoffmann C, Rockstroh JK. HIV 2012/2013. Hamburg: Medizin Fokus Verlag; 2012:280-90.
2. UNAIDS . Global Report: UNAIDS report on the global AIDS epidemic 2013. Geneva: Joint United Nations Programme on HIV/AIDS; 2013:8-15.
3. Ditjen PP&PL Kementerian Kesehatan RI. Laporan Situasi Perkembangan HIV&AIDS di Indonesia Triwulan IV Tahun 2013. Jakarta: Ditjen PP & PL Kementerian Kesehatan RI; 2013:14-24.
4. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker P, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002;16: 2447-54.
5. Piloya T, Bakeera-Kitaka S, Kekitiinwa A, Moses RK. Lipodystrophy among HIV-infected children and adolescents on higly antiretroviral therapy in Uganda: a cross sectional study. Journal of International AIDS Society. 2012;15(2):174-7.
6. Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Harrison's Principles of Internal Medicine, 18th edition. Philadelphia: McGraw-Hill; 2011: 1137-64.
7. Troll, GJ. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. Curr Atherosclerotic Repository. 2011;13:51-6.

8. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2013:27-35.
9. Villaroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active retroviral therapy in HIV infection: the adipocyte as a target of antiretroviral-induced mitochondrial toxicity. Trends Pharmacology Sciences. 2005;26(2):88-93.
10. Pujari SN, Dravid A, Naik E, Bhagat S, Tash K, Nadler JP, et al. Lipodystrophy and dyslipidemia among patients taking first-line, world health organization recommended higly active antiretroviral therapy regimens in western india. Acquired Imune Deficiency Syndrome. 2005;39:199-202.
11. Liu E, Armstrong C, Spiegelman D, Chalamilla G, Njelekela M, Hawkins C, et al. First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania. CID. 2013;56:1820-27.
12. Ceccato MGB, Bonolo PF, Souza Neto AI, Araujo FS, Freitas MIF. Antiretroviral therapy associated dyslipidemia in patients from a reference center in Brazil. Brazilian Journal of Medical and Biological Research. 2011;44:1177-83.
13. Katzung BG, Trevor AJ, Masters SB. Basic and Clinical Pharmacology 12th edition. Philadelphia: Lange; 2011:874-5.
14. Wangsomboonsri W, Mahasirimongkol S, Chantarangsu S, Kiertiburanakul, Charoenyingwattana A, Komindr S, et al. Association

between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine containing antiretroviral regimens. CID. 2010;50:597-604.

15. Domingo P, Cabeza MC, Pruvost A, Torres F, Salazar J, del Mar Gutierrez M, et al. Association of thymidine synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy. Antimicrobial Agents and Chemotherapy. 2011;55:1428-35.
16. Domingo P, Cabeza MC, Pruvost A, Salazar J, del Mar Gutierrez M, Mateo MG, et al. Relationship between HIV/higly active antiretroviral therapy-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. CID. 2010;50:1033-39.
17. Ditjen PP&PL Kementerian Kesehatan RI. Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang Dewasa dan Remaja. Jakarta: Ditjen PP & PL Kementerian Kesehatan RI; 2011:20-32.
18. Omech B, Sempa J, Castelnuovo B, Opio K, Otim M, Mayanja-Kizza H,et al. Prevalence of HIV-associated metabolic abnormalities among patients taking first line antiretroviral therapy in Uganda. IRSN AIDS. 2012;18(5): 57-62.
19. AACE. American Association of Clinical Endocrinologists guidelines for management of dyslipidemia and prevention of atherosclerosis. Jacksonville: AACE; 2012:3-12.

20. Tadewos A, Addis Z, Ambachew H, Banerjee S. Prevalence of dyslipidemia among HIV-infected patients using first line highly active antiretroviral therapy in Southern Ethipoia: a cross sectional comparative group study. AIDS Research and Therapy. 2012;9:31-6.
21. Grinspoon S, Carr A. Cardiovascular risk and body fat abnormalities in HIV-infected adults. New England Journal of Medicine. 2005;352:48-62.
22. Bennett MT. Current and future treatments of HIV-associated dyslipidemia. Future Lipidology. 2008;3(2):175-188.
23. Lagathu C, Eustace B, Prot M, et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antiviral Therapy. 2007;12(4):489-500.
24. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study. Elsevier. 2001;358:1322-27.
25. Swiecki P, Firlaq-Buckacka E, Bakowska E, Ignatowska A, Pulik P, Horban A. Study comparing lipid metabolism disorders and effectiveness of treatment in HIV-infected patients on long-term treatment with various thymidine analogue. HIV&AIDS Review. 2008;7(2):19-22.
26. Oh SW, Yoon YS, Lee ES, Kim WK, Park C,Lee S, et al. Association between cigarettes smoking and metabolic syndrome: the Korea National Health and Nutrition Examination Survey (Brief Report). Diabetes Care. 2005;28: 2064-66.

27. Miller J, Carr A, Emery S et al. HIV lipodystrophy: prevalence, severity, and correlates of risk in Australia. HIV Med. 2003;4(3):293-301.
28. Feleke Y, Fekade D, Mezegebu Y. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV-infected patients. Ethiop Med Journal. 2012;50(3):221-30.
29. Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med. 2001:2(3);174-180.
30. Van Griensven J, De Naeyer L, Mushi T et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Elsevier. 2007:101;793-8.
31. Andany N, Raboud JM, Walmsley S et al. Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. HIV Clin Trials. 2011:12(2);89-103.
32. Aragones G, Alonso-Villaverde C, Pardo-Reche P et al. Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the *APOC3*-related rs10892151 polymorphism. BMC Medical Genetics. 2011:12;120-6.
33. Anastos K, Lu D, Shi Q et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr. 2007:45(1);34-42.

34. Manuthu, EM. Prevalence of dyslipidemia and dysglycemia in HIV-infected patients at the Kenyatta National Hospital. EAMJ. 2008;85(1):10-7.
35. Hadigan C, Mazza S, Crum D, Grinspoon S. Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients. AIDS. 2007;21:2543-46.
36. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective american studies. Circulation. 1989;79:8-15.
37. Fisac C, Fumero E, Crespo M et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS.2005;19(9):17-25.
38. Schewe CK, Maserati R, Wassmer G, Adam A, Weitner L. Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment. CID. 2006;42(1):145-7.
39. Ng GWB, Chan UMS, Li PCK, Wong WCW. Can a Mediterranean diet reduce the effects of lipodystrophy syndrome in people living with HIV? A pilot randomised controlled trial. Sexual Health. 2011;8(1):43-51.
40. Szafran H, Smielak-Korombel W. The role of estrogens in hormonal regulation of lipid metabolism in women. Przeql Lek. 1998;55(5):266-70.